布地奈德福莫特罗吸入剂联合孟鲁司特治疗稳定期慢性阻塞性肺疾病患者的疗效分析

Analysis of the efficacy of budesonide and formoterol inhalation combined with montelukast in the treatment of stable chronic obstructive pulmonary disease

目的:探讨布地奈德福莫特罗吸入剂联合孟鲁司特治疗稳定期慢性阻塞性肺疾病(COPD)的临床疗效。方法:收治稳定期COPD患者120例,均给予布地奈德福莫特罗吸入剂联合孟鲁司特治疗,对患者治疗前后的肺功能及生活质量进行评价。结果:患者治疗后最大肺活量(FVC)、1秒用力呼气容积(FEV_1)以及用力呼气量占用力肺活量比值(FEV_1/FVC)均优于治疗前(P<0.05),肺功能较治疗前有明显改善,患者治疗后生活质量较治疗前也有明显改善。结论:布地奈德福莫特罗吸入剂联合孟鲁司特治疗稳定期COPD患者的临床疗效较好,对改善患者的肺功能及生活质量具有积极意义。

Objective:To investigate the clinical efficacy of budesonide and formoterol inhalation combined with montelukast in the treatment of stable chronic obstructive pulmonary disease.Methods:120 patients with stable chronic obstructive pulmonary disease were selected,they were all treated with budesonide and formoterol inhalation combined with montelukast,the lung function and quality of life of patients before and after treatment were evaluated.Results:After treatment,the maximal vital capacity(FVC),forced expiratory volume(FEV1)and forced expiratory volume occupancy ratio(FEV1/FVC)were superior to those before treatment(P<0.05),lung function improved significantly compared with that before treatment,and the quality of life of patients after treatment improved significantly compared with those before treatment.Conclusion:Budesonide and formoterol inhalation combined with montelukast has a good clinical effect in the treatment of patients with stable COPD,and it has positive significance for improving lung function and quality of life.